Cybin’s Psilocybin Therapy Shows 100% Patient Response in Depression Study

November 21, 2024

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

October 1, 2024

Cybin Holds ‘Productive’ Meeting with FDA to Discuss Plans for CYB003

August 21, 2024

Cybin Appoints Atul Mahableshwarkar as Senior VP, Clinical Development

June 16, 2024

Cybin Receives New Patent for Psilocybin Depression Treatment

April 18, 2024

Cybin Raises $150 Million Via Oversubscribed Private Placement

March 20, 2024